Actualités Roivant Sciences Ltd - ROIV | Actions NASDAQ

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

Roivant Shares Climb on Earnings Beat Despite Revenue Shortfall (ROIV)

On Wednesday, Roivant Sciences Ltd. (NASDAQ:ROIV) posted fourth-quarter adjusted earnings per share of $0.28, far surpassing analyst expectations...

Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 and Provides Business Update

IMVT-1402 showed clinically meaningful response rates of 72.7% ACR20, 54.5% ACR50 and 35.8% ACR70 at Week 16 in...

Immunovant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026, and Provide Business Update on Wednesday, May 20, 2026

DURHAM, N.C., May 11, 2026 (GLOBE NEWSWIRE) -- Immunovant (Nasdaq: IMVT) today announced that it will report...

Roivant Announces Expansion of Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP) and Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED)

Lichen planopilaris (LPP) is a highly morbid inflammatory scalp disorder that causes generally irreversible...

New England Journal of Medicine Publishes Positive Phase 3 VALOR Trial Results of Brepocitinib in Dermatomyositis

The results of the Phase 3 VALOR trial were published in the New England Journal of Medicine, underscoring the practice-changing potential of...

Moderna agrees up to $2.25 billion settlement in COVID vaccine patent dispute

Moderna (NASDAQ:MRNA) has reached a settlement worth up to $2.25 billion with Genevant Sciences, a subsidiary of Roivant Sciences (NASDAQ:ROIV...

Genevant Sciences and Arbutus Biopharma Announce $2.25 Billion Global Settlement With Moderna

Moderna to pay Genevant and Arbutus $950 million upfront and an additional $1.3 billion contingent upon a...

Roivant Secures FDA Priority Review for Dermatomyositis Treatment

Roivant Sciences Ltd (NASDAQ:ROIV) said Tuesday that the U.S. Food and Drug Administration has accepted its New Drug Application for brepocitinib...

Priovant Announces FDA Acceptance and Priority Review of New Drug Application for Brepocitinib in Dermatomyositis

FDA assigns PDUFA target action date in the third quarter of calendar year 2026 with launch expected at the end of September 2026Priority Review...

Pulmovant Announces Completion of Enrollment in the Phase 2 PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)

PHocus enrollment completed in under 12 months from first patient dosed, representing a rapid enrollment pace...

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Roivant Sciences Ltd (ROIV)

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

Roivant Sciences Ltd (ROIV) Actualités

Roivant Shares Climb on Earnings Beat Despite Revenue Shortfall (ROIV)

Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 and Provides Business Update

Immunovant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026, and Provide Business Update on Wednesday, May 20, 2026

Roivant Announces Expansion of Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP) and Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED)

New England Journal of Medicine Publishes Positive Phase 3 VALOR Trial Results of Brepocitinib in Dermatomyositis

Moderna agrees up to $2.25 billion settlement in COVID vaccine patent dispute

Genevant Sciences and Arbutus Biopharma Announce $2.25 Billion Global Settlement With Moderna

Roivant Secures FDA Priority Review for Dermatomyositis Treatment

Priovant Announces FDA Acceptance and Priority Review of New Drug Application for Brepocitinib in Dermatomyositis

Pulmovant Announces Completion of Enrollment in the Phase 2 PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Roivant Sciences Ltd (ROIV)

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

Roivant Sciences Ltd (ROIV) Actualités

Roivant Shares Climb on Earnings Beat Despite Revenue Shortfall (ROIV)

Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 and Provides Business Update

Immunovant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026, and Provide Business Update on Wednesday, May 20, 2026

Roivant Announces Expansion of Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP) and Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED)

New England Journal of Medicine Publishes Positive Phase 3 VALOR Trial Results of Brepocitinib in Dermatomyositis

Moderna agrees up to $2.25 billion settlement in COVID vaccine patent dispute

Genevant Sciences and Arbutus Biopharma Announce $2.25 Billion Global Settlement With Moderna

Roivant Secures FDA Priority Review for Dermatomyositis Treatment

Priovant Announces FDA Acceptance and Priority Review of New Drug Application for Brepocitinib in Dermatomyositis

Pulmovant Announces Completion of Enrollment in the Phase 2 PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Sign up for FREE and get:

Supprimer les publicités